| Body na spoluautora | Body za publikaci pro MU | Odkaz ISVaV | | 0,00 | 0,00 | VPLYV BUPROPIONU A POHLAVIA NA METABOLICKÚ AKTIVITU PEČEŇOVEJ IZOFORMY CYP2D2 V PREKLINICKOM EXPERIMENTE
|
| 0,00 | 0,00 | Gender-dependent influence of bupropion on the activity of hepatic cytochrome P450 2D2 in rats
|
| 3,09 | 12,37 | Evaluation of the activity of P450 enzymes in rats: use of the single marker or combined drug administration.
|
| 0,00 | 0,00 | Stanovení diklofenaku a 4-hydroxydiklofenaku jako markeru metabolické aktivity CYP2C9
|
| 1,12 | 5,62 | Význam genotypu a fenotypu CYP2D6 při léčbě paroxetinem
|
| 0,70 | 2,81 | Vliv metamfetaminu na biotransformační procesy cytochromu P450
|
| 0,47 | 2,81 | Změny působení metamfetaminu při současném užití antidepresiva fluoxetinu v preklinických modelech
|
| 0,00 | 0,00 | RYCHLÉ HPLC STANOVENÍ FENOTYPU CYP 1A, 2C A 3A Z PERFUZÁTU IZOLOVANÝCH JATER POTKANA
|
| 0,94 | 2,81 | Polyfarmakoterapie u pacienta s pomalým metabolickýcm genotypem CYP2D6
|
| 3,83 | 22,95 | Effect of St John's wort (Hypericum perforatum) on cytochrome P-450 activity in perfused rat liver
|
| 1,14 | 8,00 | Effect of methamphetamine on pharmacokinetics of dextromethorphan and midazolam.
|
| 12,86 | 77,18 | Effect of fluoxetine on methamphetamine biodegradation in methamphetamine dependence
|
| 1,14 | 8,00 | Feet of methamphetamine on pharmacokinetics of dextromethorphan and midazolam in rats.
|
| 3,60 | 21,60 | Effect of acute and sub-chronic administration of methamphetamine on activity of CYP2D in isolated perfused rat liver.
|
| 0,00 | 0,00 | Comparative study on the influence of methamphetamine and enzyme inducers on the activity of drug-metabolizing enzymes in the rat liver microsomes
|
| 3,60 | 21,60 | Effect of acute and repeated administration of methamphetamine on the activity of CYP2D in isolated perfused rat liver
|
| 0,51 | 2,56 | Clinical impact of CYP2D6 activity in long-term paroxetine treatment
|
| 0,00 | 0,00 | Determination of midazolam and its metabolites in rat plasma and perfuse medium by HPLC
|
| 0,00 | 0,00 | Determination of nifedipine as a probe substrate of cytochrome P450 3A1/2 activity in rats
|
| 2,81 | 5,62 | COMPARISON OF THE INFLUENCE OF METHAMPHETAMINE AND PHENOBARBITAL ON THE ACTIVITY OF HEPATIC MICROSOMAL MONOOXYGENASES IN THE RAT
|
| 0,00 | 0,00 | Léčba antidepresivy: volba dle aktivity CYP2D6 a pohlaví
|
| 0,00 | 0,00 | Link between paroxetine-induced sexual dysfunction, gender and acitivity CYP2D6
|
| 0,00 | 0,00 | Mentální bulimie, léčba paroxetinem a ovlivnění aktivity CYP2D6 (předběžné výsledky)
|
| 1,12 | 5,62 | Léčba antidepresivy: volba dle aktivity CYP2D6 a pohlaví
|
| 0,00 | 0,00 | HPLC STANOVENÍ MIDAZOLAMU A JEHO METABOLITŮ V PLAZMĚ A PERFUZNÍM MEDIU
|
| 1,12 | 5,62 | The influence of gender on metabolic activity of enzymatic system of cytochrome P450 in the model of isolated perfused rat liver.
|
| 1,87 | 9,36 | Molecular genetic detection of alleles of the CYP2D6 gene in patinets with depression or anxiety disorders
|
| 0,00 | 0,00 | Modulating effects of CB1 agonist methananadamide on the activity of CYP450 isoenzymes in rat
|
| 1,56 | 9,36 | Možnosti aplikace testování aktivity CYP2D6: přehled dosavadních výsledků více než desetileté spolupráce genetiky, farmakologie a psychiatrei
|
| 8,43 | 50,56 | HPLC determination of midazolam and its three hydroxy metabolites in perfusion medium and plasma from rats
|
| 0,00 | 0,00 | The influence of diet on metabolic activity of cytochrome P450
|
| 1,40 | 5,62 | THE INFLUENCE OF CANNABINOID METHANANDAMIDE ON THE ACTIVITY OF HEPATIC CYP2D2 IN RATS
|
| 0,00 | 0,00 | Dynamika fenotypu CYP2D6 u léčby mentální bulimie paroxetinem
|
| 3,14 | 12,56 | THE INFLUENCE OF METHANANDAMIDE AND SEX ON THE ACTIVITY OF CYTOCHROME P 450 AS A PREDICTIVE FACTOR OF XENOBIOTICS TOXICITY
|
| 19,30 | 77,18 | Gender-dependent influence of bupropion pretreatment on locomotor activity and the activity of hepatic CYP2D2 in rats
|
| 13,59 | 54,36 | Fading of the inhibition of CYP2D6 after paroxetine treatment discontinuation
|
| 0,00 | 0,00 | Can methanandamide and gender influence pharmacokinetics of psychoactive drugs?
|
| 5,06 | 25,32 | Mental bulimia and paroxetine treatment - monitoring CYP2D6 activity (preliminary results)
|
| 0,00 | 0,00 | Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity
|
| 0,00 | 0,00 | Mentální bulimie a léčba paroxetinem, sledování aktivity CYP2D6
|
| 19,30 | 77,18 | Links among paroxetine-induced sexual dysfunctions, gender, and CYP2D6 activity
|
| 0,00 | 0,00 | Simultaneous HPLC determination of markers of metabolic activity of CYP1A2 and CYP2C6
|
| 0,00 | 0,00 | VPLYV METANANDAMIDU NA AKTIVITU CYTOCHRÓMU P450 AKO PREDIKČNÉHO FAKTORU TOXICITY XENOBIOTÍK
|
| 0,00 | 0,00 | Změny fenotypu CYP2D6 u pacientek s mentální bulimií léčených paroxetinem
|
Back
(c) Michal Bulant, 2011